212 related articles for article (PubMed ID: 3282467)
1. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
[TBL] [Abstract][Full Text] [Related]
3. Deoxycoformycin in the treatment of leukemias and lymphomas.
Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
[TBL] [Abstract][Full Text] [Related]
4. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
[TBL] [Abstract][Full Text] [Related]
5. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
6. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
Spiers AS
Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.
Spiers AS; Ruckdeschel JC; Horton J
Scand J Haematol; 1984 Feb; 32(2):130-4. PubMed ID: 6608139
[TBL] [Abstract][Full Text] [Related]
8. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
[TBL] [Abstract][Full Text] [Related]
9. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
Spiers AS
Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
[No Abstract] [Full Text] [Related]
10. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
[TBL] [Abstract][Full Text] [Related]
11. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
[TBL] [Abstract][Full Text] [Related]
13. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
Spiers AS; Parekh SJ
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
[No Abstract] [Full Text] [Related]
14. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
16. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Macdonald JS; Marsoni S; Bruno S; Poster D
Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
[TBL] [Abstract][Full Text] [Related]
17. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
Grever MR; Bisaccia E; Scarborough DA; Metz EN; Neidhart JA
Blood; 1983 Feb; 61(2):279-82. PubMed ID: 6600401
[TBL] [Abstract][Full Text] [Related]
18. 2'-deoxycoformycin. A new anticancer agent.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
[TBL] [Abstract][Full Text] [Related]
19. Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.
Ho AD; Ganeshaguru K
Klin Wochenschr; 1988 Jun; 66(11):467-74. PubMed ID: 2841534
[TBL] [Abstract][Full Text] [Related]
20. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).
Spiers AS; Moore D; Cassileth PA; Harrington DP; Cummings FJ; Neiman RS; Bennett JM; O'Connell MJ
N Engl J Med; 1987 Apr; 316(14):825-30. PubMed ID: 2434850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
